<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223938</url>
  </required_header>
  <id_info>
    <org_study_id>FR02023</org_study_id>
    <nct_id>NCT00223938</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.</brief_title>
  <official_title>A Multi-center, Open-label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the&#xD;
      maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients&#xD;
      receiving Erythropoietin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Open-Label, Parallel Group Study of the efficacy and safety of Ferrlecit in&#xD;
      the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients&#xD;
      Receiving Erythropoietin. Patients with normal iron indices receive one of two doses of&#xD;
      Ferrlecit administered weekly throughout the treatment period. Efficacy was assesses at&#xD;
      designated timepoints throughout the study and after the last Ferrlecit dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated because of significant enrollment challenges&#xD;
  </why_stopped>
  <start_date type="Actual">December 30, 2003</start_date>
  <completion_date type="Actual">April 27, 2007</completion_date>
  <primary_completion_date type="Actual">April 27, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to evaluate the efficacy of two dose levels of Ferrlecit when compared with oral iron when administered as maintenance therapy in iron-replete hemodialysis patients who are receiving Erythropoietin.</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of this study include comparisons between Ferrlecit treatments to oral iron regarding changes from baseline in hematological parameters, iron indices, EPO requirements and safety.</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium ferric gluconate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium ferric gluconate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Iron</intervention_name>
    <description>Oral Iron</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ferrous sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium ferric gluconate</intervention_name>
    <description>weekly intravenous injection Dose 1</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ferrlecit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium ferric gluconate</intervention_name>
    <description>weekly intravenous injection Dose 2</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Ferrlecit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male of female, 18 years old or older.&#xD;
&#xD;
          -  Have been receiving chronic hemodialysis therapy&#xD;
&#xD;
          -  On stable EPO dosing regimen.&#xD;
&#xD;
          -  Have signed patient informed consent.&#xD;
&#xD;
          -  Predetermined serum ferritin and TSAT levels.&#xD;
&#xD;
          -  Clinical instability - inability to achieve adequate dialysis, abnormal serum albumin&#xD;
             and serum glucose.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  A known sensitivity to Ferrlecit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Scheduled for renal transplant.&#xD;
&#xD;
          -  A serious concomitant medical disorders incompatible with participation in the study.&#xD;
&#xD;
          -  Unable to cooperate or comply with the protocol.&#xD;
&#xD;
          -  Use of any investigation agent within 30 days prior to study or during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Judged by the investigator as unsuitable for enrollment for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Hoel, RPh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Watson Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <name_title>Gary Hoel PhD Executive Director</name_title>
    <organization>Watson</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric gluconate</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

